Last reviewed · How we verify
TNX-355
At a glance
| Generic name | TNX-355 |
|---|---|
| Sponsor | Tanox |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (PHASE1)
- CD4CAR for CD4+ Leukemia and Lymphoma (PHASE1)
- Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant (PHASE1)
- A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
- Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (PHASE1)
- External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNX-355 CI brief — competitive landscape report
- TNX-355 updates RSS · CI watch RSS
- Tanox portfolio CI